Grace Therapeutics, Inc. (GRCE) intrinsic value & 10-year financials
Grace Therapeutics, Inc. (GRCE) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.89
- Market cap
- $31.2M
- Revenue (FY2026)
- —
- ROIC (10-yr avg)
- 375.1%
- Free cash flow (FY2026)
- —
GRCE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2026 | — | -$7.8M | -$0.47 | — | — | -13.9% |
| FY2025 | — | -$9.6M | -$0.79 | — | — | -32.3% |
| FY2024 | — | -$12.9M | -$1.35 | — | — | -28.4% |
| FY2023 | — | -$42.4M | -$0.95 | — | — | -71.8% |
| FY2022 | $0 | -$9.8M | -$0.27 | — | — | -18.7% |
| FY2021 | $196.0K | -$19.7M | — | — | -8377.0% | 1397.4% |
| FY2020 | — | -$25.5M | — | — | — | 2079.8% |
| FY2019 | — | -$39.4M | — | — | — | -311.5% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Grace Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Grace Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -16.7% ROIC.
Grace Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Grace Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.